Amgen Inc.
ืœื•ื ื’

๐Ÿ”ฌ๐Ÿ’Š Amgen Innovations & Strategic Moves ๐Ÿš€

152
๐ŸŒŸ Lumakras Breakthrough:
Amgen (AMGN) pioneers cancer treatment with Lumakras, the first medication targeting a mutation found in approximately 13% of lung cancer patients.

๐Ÿ’ฐ Strategic Acquisition:
Amgen acquires Horizon Therapeutics for a substantial $28 billion in cash.
Incorporates Tepezza, an FDA-approved medicine for thyroid eye disease, into Amgen's product portfolio.

๐Ÿ“ˆ Market Outlook:
Bullish stance on AMGN suggests support levels above $260.00-$265.00.
Anticipated upside target in the range of $360.00-$365.00.

Exciting developments in biotech and strategic expansion for Amgen! ๐ŸŒ๐Ÿ’‰

#AmgenInnovation #Biotech #StockMarket ๐Ÿ“ฐ๐Ÿ“Š

ื›ืชื‘ ื•ื™ืชื•ืจ

ื”ืžื™ื“ืข ื•ื”ืคืจืกื•ืžื™ื ืื™ื ื ืžื™ื•ืขื“ื™ื ืœื”ื™ื•ืช, ื•ืื™ื ื ืžื”ื•ื•ื™ื, ื™ื™ืขื•ืฅ ืื• ื”ืžืœืฆื” ืคื™ื ื ืกื™ืช, ื”ืฉืงืขืชื™ืช, ืžืกื—ืจื™ืช ืื• ืžื›ืœ ืกื•ื’ ืื—ืจ ื”ืžืกื•ืคืงืช ืื• ืžืื•ืฉืจืช ืขืœ ื™ื“ื™ TradingView. ืงืจื ืขื•ื“ ื‘ึพืชื ืื™ ื”ืฉื™ืžื•ืฉ.